Plasmid-Based CRISPR-Cas9 Gene Editing in Multiple Candida Species

被引:2
|
作者
Lombardi, Lisa [1 ]
Oliveira-Pacheco, Joao [1 ]
Butler, Geraldine [1 ]
机构
[1] Univ Coll Dublin, Sch Biomol & Biomed Sci, Conway Inst, Dublin, Ireland
来源
MSPHERE | 2019年 / 4卷 / 02期
基金
爱尔兰科学基金会; 欧盟地平线“2020”;
关键词
CRISPR; Candida; genome; WEB TOOL; PARAPSILOSIS; PATHOGEN; DISRUPTION; CHOPCHOP; DELETION; ALBICANS;
D O I
10.1128/mSphere.00125-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Many Candida species that cause infection have diploid genomes and do not undergo classical meiosis. The application of clustered regularly interspaced short palindromic repeat-Cas9 (CRISPR-Cas9) gene editing systems has therefore greatly facilitated the generation of gene disruptions and the introduction of specific polymorphisms. However, CRISPR methods are not yet available for all Candida species. We describe here an adaption of a previously developed CRISPR system in Candida parapsilosis that uses an autonomously replicating plasmid. Guide RNAs can be introduced in a single cloning step and are released by cleavage between a tRNA and a ribozyme. The plasmid also contains CAS9 and a selectable nourseothricin SAT1 marker. It can be used for markerless editing in C. parapsilosis, C. orthopsilosis, and C. metapsilosis. We also show that CRISPR can easily be used to introduce molecular barcodes and to reintroduce wild-type sequences into edited strains. Heterozygous mutations can be generated, either by careful selection of the distance between the polymorphism and the Cas9 cut site or by providing two different repair templates at the same time. In addition, we have constructed a different autonomously replicating plasmid for CRISPR-Cas9 editing in Candida tropicalis. We show that editing can easily be carried out in multiple C. tropicalis isolates. Nonho-mologous end joining (NHEJ) repair occurs at a high level in C. metapsilosis and C. tropicalis. IMPORTANCE Candida species are a major cause of infection worldwide. The species associated with infection vary with geographical location and with patient population. Infection with Candida tropicalis is particularly common in South America and Asia, and Candida parapsilosis infections are more common in the very young. Molecular methods for manipulating the genomes of these species are still lacking. We describe a simple and efficient CRISPR-based gene editing system that can be applied in the C. parapsilosis species group, including the sister species Candida orthopsilosis and Candida metapsilosis. We have also constructed a separate system for gene editing in C. tropicalis.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies
    Papizan, James B.
    Porter, Shaina N.
    Sharma, Akshay
    Pruett-Miller, Shondra M.
    JOURNAL OF BIOMEDICAL RESEARCH, 2021, 35 (02): : 115 - 134
  • [32] CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
    Mehta, Jayesh
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (23):
  • [33] SYNCAS based CRISPR-Cas9 gene editing in predatory mites, whiteflies and stinkbugs
    Mocchetti, A.
    De Rouck, S.
    Naessens, S.
    Dermauw, W.
    Van Leeuwen, T.
    INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2025, 177
  • [34] CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential
    Blenke, Erik Oude
    Evers, Martijn J. W.
    Mastrobattista, Enrico
    van der Oost, John
    JOURNAL OF CONTROLLED RELEASE, 2016, 244 : 139 - 148
  • [35] Modelling the Cancer Phenotype in the Era of CRISPR-Cas9 Gene Editing
    Stewart, J.
    Banerjee, S.
    Pettitt, S. J.
    Lord, C. J.
    CLINICAL ONCOLOGY, 2020, 32 (02) : 69 - 74
  • [36] Recent Progress in Regulating CRISPR-Cas9 System for Gene Editing
    Gong Shaohua
    Li Na
    Tang Bo
    ACTA CHIMICA SINICA, 2020, 78 (07) : 634 - 641
  • [37] Is microfluidics the "assembly line" for CRISPR-Cas9 gene-editing?
    Ahmadi, Fatemeh
    Quach, Angela B. V.
    Shih, Steve C. C.
    BIOMICROFLUIDICS, 2020, 14 (06)
  • [38] Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies
    James B.Papizan
    Shaina N.Porter
    Akshay Sharma
    Shondra M.Pruett-Miller
    The Journal of Biomedical Research, 2021, 35 (02) : 115 - 134
  • [39] The Potential Harms of Human Gene Editing Using CRISPR-Cas9
    Baylis, Francoise
    CLINICAL CHEMISTRY, 2018, 64 (03) : 489 - 491
  • [40] CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
    Lakshmi, Dhanya N.
    INDIAN PEDIATRICS, 2022, 59 (06) : 458 - 458